Your browser doesn't support javascript.
loading
Clinical potential of introducing next-generation sequencing in patients at relapse of acute myeloid leukemia.
Flach, Johanna; Shumilov, Evgenii; Wiedemann, Gertrud; Porret, Naomi; Shakhanova, Inna; Bürki, Susanne; Legros, Myriam; Joncourt, Raphael; Pabst, Thomas; Bacher, Ulrike.
Afiliação
  • Flach J; Department of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany.
  • Shumilov E; Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), Göttingen, Germany.
  • Wiedemann G; University Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland.
  • Porret N; Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland.
  • Shakhanova I; University Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland.
  • Bürki S; Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland.
  • Legros M; Department of Nephrology and Rheumatology, University Medicine Göttingen (UMG), Göttingen, Germany.
  • Joncourt R; Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.
  • Pabst T; Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland.
  • Bacher U; University Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland.
Hematol Oncol ; 38(4): 425-431, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32306411
Relapse of acute myeloid leukemia (AML) remains a major determinant of outcome. A number of molecularly directed treatment options have recently emerged making comprehensive diagnostics an important pillar of clinical decision making at relapse. Acknowledging the high degree of individual genetic variability at AML relapse, next-generation sequencing (NGS) has opened the opportunity for assessing the unique clonal hierarchy of individual AML patients. Knowledge on the genetic makeup of AML is reflected in patient customized treatment strategies thereby providing improved outcomes. For example, the emergence of druggable mutations at relapse enable the use of novel targeted therapies, including FLT3 inhibitors or the recently approved IDH1/2 inhibitors ivosidenib and enasidenib, respectively. Consequently, some patients may undergo novel bridging approaches for reinduction before allogeneic stem cell transplantation, or the identification of an adverse prognostic marker may initiate early donor search. In this review, we summarize the current knowledge of NGS in identifying clonal stability, clonal evolution, and clonal devolution in the context of AML relapse. In light of recent improvements in AML treatment options, NGS-based molecular diagnostics emerges as the basis for molecularly directed treatment decisions in patients at relapse.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Sequenciamento de Nucleotídeos em Larga Escala / Mutação / Proteínas de Neoplasias / Recidiva Local de Neoplasia / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Hematol Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Sequenciamento de Nucleotídeos em Larga Escala / Mutação / Proteínas de Neoplasias / Recidiva Local de Neoplasia / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Hematol Oncol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha